var data={"title":"Aspirin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aspirin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5673?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">see &quot;Aspirin: Drug information&quot;</a> and <a href=\"topic.htm?path=aspirin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aspirin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137093\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ascriptin Maximum Strength [OTC];</li>\n      <li>Ascriptin Regular Strength [OTC];</li>\n      <li>Aspercin [OTC];</li>\n      <li>Aspir-low [OTC];</li>\n      <li>Aspirtab [OTC];</li>\n      <li>Bayer Aspirin Extra Strength [OTC];</li>\n      <li>Bayer Aspirin Regimen Adult Low Strength [OTC];</li>\n      <li>Bayer Aspirin Regimen Children's [OTC];</li>\n      <li>Bayer Aspirin Regimen Regular Strength [OTC];</li>\n      <li>Bayer Genuine Aspirin [OTC];</li>\n      <li>Bayer Plus Extra Strength [OTC];</li>\n      <li>Bayer Women's Low Dose Aspirin [OTC];</li>\n      <li>Buffasal [OTC];</li>\n      <li>Bufferin Extra Strength [OTC];</li>\n      <li>Bufferin [OTC];</li>\n      <li>Buffinol [OTC];</li>\n      <li>Durlaza;</li>\n      <li>Ecotrin Arthritis Strength [OTC];</li>\n      <li>Ecotrin Low Strength [OTC];</li>\n      <li>Ecotrin [OTC];</li>\n      <li>Halfprin [OTC] [DSC];</li>\n      <li>St Joseph Adult Aspirin [OTC];</li>\n      <li>Tri-Buffered Aspirin [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137094\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Asaphen;</li>\n      <li>Asaphen E.C.;</li>\n      <li>Entrophen;</li>\n      <li>Novasen;</li>\n      <li>Praxis ASA EC 81 Mg Daily Dose;</li>\n      <li>Pro-AAS EC-80</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051174\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Nonopioid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiplatelet Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antipyretic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Salicylate</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12669217\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Antiplatelet effects; p</b>\n      <b>ostoperative congenital heart repair or recurrent arterial ischemic stroke: </b>Limited data available: Full-term neonate: Oral: Adequate neonatal studies have not been performed; neonatal dosage is derived from clinical experience and is not well established; suggested doses: 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]). Doses are typically rounded to a convenient amount (eg, <sup>1</sup>/<sub>4</sub> of 81 mg tablet)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051166\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">see &quot;Aspirin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Doses are typically rounded to a convenient amount (eg, <sup>1</sup>/<sub>4</sub> of 81 mg tablet):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesic:</b> Oral, rectal: <b>Note:</b> Do not use aspirin in pediatric patients &lt;18 years who have or who are recovering from chickenpox or flu symptoms (eg, viral illness) due to the association with Reye syndrome (APS 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents weighing &lt;50 kg: Limited data available: 10 to 15 mg/kg/dose every 4 to 6 hours; maximum daily dose: 90 mg/kg/<b>day</b> or 4,000 mg/<b>day</b> whichever is less (APS 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents weighing &ge;50 kg: 325 to 650 mg every 4 to 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anti-inflammatory:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 60 to 90 mg/kg/<b>day</b> in divided doses; usual maintenance: 80 to 100 mg/kg/<b>day</b> divided every 6 to 8 hours; monitor serum concentrations (Levy 1978)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antiplatelet effects:</b> Limited data available: Infants, Children, and Adolescents: Oral: Adequate pediatric studies have not been performed; pediatric dosage is derived from adult studies. Usual adult maximum daily dose for antiplatelet effects is 325 mg/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acute ischemic stroke (AIS):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Noncardioembolic: 1 to 5 mg/kg/dose once daily for &ge;2 years; patients with recurrent AIS or TIAs should be transitioned to clopidogrel, LMWH, or warfarin (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Secondary to Moyamoya and non-Moyamoya vasculopathy: 1 to 5 mg/kg/dose once daily; <b>Note:</b> In non-Moyamoya vasculopathy, continue aspirin for 3 months, with subsequent use guided by repeat cerebrovascular imaging (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prosthetic heart valve: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bioprosthetic aortic valve (with normal sinus rhythm): 1 to 5 mg/kg/dose once daily for 3 months (AHA [Giglia 2013]; ACCP [Guyatt 2012]; ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mechanical aortic and/or mitral valve: 1 to 5 mg/kg/dose once daily combined with vitamin K antagonist (eg, warfarin) is recommended as first-line antithrombotic therapy (ACCP [Guyatt 2012]; ACCP [Monagle 2012]). Alternative regimens: 6 to 20 mg/kg/dose once daily in combination with dipyridamole (Bradley 1985; el Makhlouf 1987; LeBlanc 1993; Serra 1987; Solymar 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Shunts: Blalock-Taussig; Glenn; postoperative; primary prophylaxis:</i> 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]; AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Norwood, Fontan surgery, postoperative; primary prophylaxis:</i> 1 to 5 mg/kg/dose once daily (ACCP [Monagle 2012]; AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transcatheter Atrial Septal Defect (ASD) or Ventricular Septal Defect (VSD) devices, postprocedure prophylaxis:</i> 1 to 5 mg/kg/dose once daily starting one to several days prior to implantation and continued for at least 6 months. For older children and adolescents, after device closure of ASD, an additional anticoagulant may be given with aspirin for 3 to 6 months, but the aspirin should continue for at least 6 months (AHA [Giglia 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ventricular assist device (VAD) placement:</i> 1 to 5 mg/kg/dose once daily initiated within 72 hours of VAD placement; should be used with heparin (initiated between 8 to 48 hours following implantation) and with or without dipyridamole (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease:</b> Limited data available; optimal dose not established: <b>Note:</b> Patients with Kawasaki disease and presenting with influenza or viral illness should not receive aspirin; acetaminophen is suggested as an antipyretic in these patients and an alternate antiplatelet agent suggested for a minimum of 2 weeks (AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial therapy (acute phase): Recommended dosing regimens vary. Use in combination with IV immune globulin (within first 10 days of symptom onset) and corticosteroids in some cases.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>High dose</i>: 80 to 100 mg/kg/<b>day</b> divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AAP [<i>Red Book</i> 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i> Moderate dose:</i> 30 to 50 mg/kg/<b>day</b> divided every 6 hours for up to 14 days until fever resolves for at least 48 to 72 hours (AHA [McCrindle 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Subsequent therapy (low-dose; antiplatelet effects): 3 to 5 mg/kg/<b>day</b> once daily; reported dosing range: 1 to 5 mg/kg/day; initiate after fever resolves for at least 48 to 72 hours (or after 14 days). In patients without coronary artery abnormalities, administer the lower dose for 6 to 8 weeks. In patients with coronary artery abnormalities, low-dose aspirin should be continued indefinitely (in addition to therapy with warfarin) (AAP [<i>Red Book</i> 2015]; ACCP [Monagle 2012]; AHA [Giglia 2013]; AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatic fever:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 100 mg/kg/<b>day</b> divided into 4 to 5 doses; if response inadequate, may increase dose to 125 mg/kg/<b>day</b>; continue for 2 weeks; then decrease dose to 60 to 70 mg/kg/<b>day</b> in divided doses for an additional 3 to 6 weeks (WHO Guidelines 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Migratory polyarthritis, with carditis without cardiomegaly or congestive heart failure:</i> Initial: 100 mg/kg/<b>day</b> in 4 divided doses for 3 to 5 days, followed by 75 mg/kg/<b>day</b> in 4 divided doses for 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carditis and cardiomegaly or congestive heart failure:</i> At the beginning of the tapering of the prednisone dose, aspirin should be started at 75 mg/kg/<b>day</b> in 4 divided doses for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> For most cardiovascular uses, typical maintenance dosing of aspirin is 81 mg once daily. Manufacturer recommended dosing for some indications have been superseded by more recent guideline recommended doses and therefore manufacturer recommended dosing may not be represented; terminologies may also differ from manufacturer's prescribing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesic and antipyretic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: 325 to 650 mg as needed every 4 hours<b> or</b> 975 mg as needed every 6 hours <b>or</b> 500 to 1,000 mg as needed every 4 to 6 hours for no more than 10 days or as directed by health care provider; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: 300 to 600 mg every 4 hours; for no more than 10 days or as directed by health care provider; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coronary artery disease (CAD), established or chronic:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 75 to 100 mg once daily (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release capsule: 162.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute Ischemic Stroke/TIA:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 160 to 325 mg within 48 hours of stroke/TIA onset, followed by 75 to 100 mg once daily (ACCP [Guyatt 2012]). The AHA/ASA recommends an initial dose of 325 mg within 24 to 48 hours after stroke; do not administer aspirin within 24 hours after administration of alteplase (Jauch 2013). The combination of aspirin and clopidogrel might be considered within 24 hours of a minor ischemic stroke or TIA and continued for 21 days (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release capsule: Maintenance (secondary prevention): 162.5 mg once daily. <b>Note:</b> Not for initial dosing during acute ischemic stroke or TIA (use immediate release).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no recommendations in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &ge;10 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Dialyzable: 50% to 100%; administer daily dose after dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CRRT: No dosage adjustment necessary; monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Analgesia or anti-inflammatory uses:</i> The manufacturer recommends avoiding in patients with CrCl &lt;10 mL/minute. However, may use with caution and monitor renal function or consider the use of an alternative analgesic/anti-inflammatory agent (NKF [Henrich 1996], Whelton 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Antiplatelet uses:</i> The manufacturer recommends avoiding in patients with CrCl &lt;10 mL/minute. However, in general, the benefit of low-dose aspirin outweighs any risk associated with nephropathy or other adverse effects even in the setting of severe renal impairment; the recommended aspirin dose should not be reduced in any patient with suspected or documented ACS, other cardiovascular disease, or other antithrombotic indication (Fernandez 2001; Harter 1979; Summaria 2015). In patients with diabetes and chronic kidney disease or in dialysis patients, the National Kidney Foundation recommends the use of antithrombotic doses of aspirin (ie, 75 to 162 mg daily) for prevention and management of ischemic heart disease or primary prevention of atherosclerotic disease (KDOQI 2005, KDOQI 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Dialyzable (concentration dependent; higher salicylate concentrations are more readily dialyzable: 50% to 60%) (Juurlink 2015; Rosenberg 1981); consider administration after hemodialysis on dialysis days (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All ages: Avoid use in severe liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137065\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, oral: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Extra Strength: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Genuine Aspirin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Women's Low Dose Aspirin: 81 mg [contains elemental calcium 300 mg]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, oral [buffered]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ascriptin Maximum Strength: 500 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Plus Extra Strength: 500 mg [contains calcium carbonate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, enteric coated, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Regular Strength: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule Extended Release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Durlaza: 162.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository, rectal: 300 mg (12s); 600 mg (12s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aspercin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aspirtab: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Genuine Aspirin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral [buffered]: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ascriptin Regular Strength: 325 mg [contains aluminum hydroxide, calcium carbonate, magnesium hydroxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buffasal: 325 mg [contains magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bufferin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bufferin Extra Strength: 500 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buffinol: 324 mg [sugar free; contains magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tri-Buffered Aspirin: 325 mg [contains calcium carbonate, magnesium carbonate, magnesium oxide]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, chewable, oral: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Children's: 81 mg [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Children's: 81 mg [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">St Joseph Adult Aspirin: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, enteric coated, oral: 81 mg, 325 mg, 650 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aspir-low: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bayer Aspirin Regimen Adult Low Strength: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin: 325 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin Arthritis Strength: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin Low Strength: 81 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Halfprin: 81 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">St Joseph Adult Aspirin: 81 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137050\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051179\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Administer with water, food, or milk to decrease GI upset. Do not crush or chew enteric coated tablets; these preparations should be swallowed whole. For acute myocardial infarction, have patient chew immediate release tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release capsules: Do not cut, crush, or chew. Administer with a full glass of water at the same time each day. Do not administer 2 hours before or 1 hour after alcohol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Remove suppository from plastic packet and insert into rectum as far as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137087\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store oral dosage forms (caplets, tablets, capsules) at room temperature; protect from moisture; see product-specific labeling for details. Keep suppositories in refrigerator; do not freeze. Hydrolysis of aspirin occurs upon exposure to water or moist air, resulting in salicylate and acetate, which possess a vinegar-like odor. Do not use if a strong odor is present.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051178\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Treatment of mild to moderate pain, inflammation, and fever (OTC: All products: FDA approved in adults; refer to product-specific information regarding FDA approval in pediatric patients, most products FDA approved in ages &ge;12 years), has also been used for adjunctive treatment of Kawasaki disease; prevention of vascular mortality during suspected acute MI; prevention of recurrent MI; prevention of MI in patients with angina; prevention of recurrent stroke and mortality following TIA or stroke; management of rheumatoid arthritis, and rheumatic fever; adjunctive therapy in revascularization procedures (coronary artery bypass graft, percutaneous transluminal coronary angioplasty, carotid endarterectomy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Reduce the risk of death and MI in patients with chronic coronary artery disease (eg, history of MI, unstable angina, or chronic stable angina); reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack (TIA) (All indications: FDA approved in adults). <b>Note</b>: Do not use extended release capsules in situations for which a rapid onset of action is required (such as acute treatment of MI or before percutaneous coronary intervention); use immediate release formulations instead.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137154\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aspirin may be confused with Afrin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ascriptin may be confused with Aricept</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ecotrin may be confused with Edecrin, Epogen</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Halfprin may be confused with Haltran</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ZORprin may be confused with Zyloprim</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cartia [multiple international markets] may be confused with Cartia XT brand name for dilTIAZem [US]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Aspirin, when used chronically at doses more than 325 mg, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, when aspirin is used for the primary prevention of cardiac events, it should be used with caution in older adults 80 years and older due to a lack of evidence of benefit versus risk (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137152\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs which may affect hemostasis, bleeding is associated with aspirin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables including dosage, concurrent use of multiple agents which alter hemostasis, and patient susceptibility. Many adverse effects of aspirin are dose related, and are extremely rare at low dosages. Other serious reactions are idiosyncratic, related to allergy or individual sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Cardiac arrhythmia, edema, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, cerebral edema, coma, confusion, dizziness, fatigue, headache, hyperthermia, insomnia, lethargy, nervousness, Reye's syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, dehydration, hyperglycemia, hyperkalemia, hypernatremia (buffered forms), hypoglycemia (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Duodenal ulcer, dyspepsia, epigastric distress, gastritis, gastrointestinal erosion, gastrointestinal ulcer, heartburn, nausea, stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Postpartum hemorrhage, prolonged gestation, prolonged labor, proteinuria, stillborn infant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, blood coagulation disorder, disseminated intravascular coagulation, hemolytic anemia, hemorrhage, iron deficiency anemia, prolonged prothrombin time, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis (reversible), hepatotoxicity, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Acetabular bone destruction, rhabdomyolysis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Hearing loss, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis, renal failure (including cases caused by rhabdomyolysis), renal insufficiency, renal papillary necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchospasm, dyspnea, hyperventilation, laryngeal edema, noncardiogenic pulmonary edema, respiratory alkalosis, tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Low birth weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anorectal stenosis (suppository), atrial fibrillation (toxicity), cardiac conduction disturbance (toxicity), cerebral infarction (ischemic), cholestatic jaundice, colitis, colonic ulceration, coronary artery vasospasm, delirium, esophageal obstruction, esophagitis (with esophageal ulcer), hematoma (esophageal), macular degeneration (age-related) (Li 2014), periorbital edema, rhinosinusitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137072\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to NSAIDs; patients with asthma, rhinitis, and nasal polyps; use in children or teenagers for viral infections, with or without fever.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for salicylates is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137054\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tinnitus: Discontinue use if tinnitus or impaired hearing occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Upper gastrointestinal (UGI) events (eg, symptomatic or complicated ulcers): Low-dose aspirin for cardioprotective effects is associated with a two- to fourfold increase in UGI events. The risks of these events increase with increasing aspirin dose; during the chronic phase of aspirin dosing, doses &gt;81 mg are not recommended unless indicated (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Use with caution in patients with dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Heavy ethanol use (&gt;3 drinks/day) can increase bleeding risks and may enhance gastric mucosal damage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis. Avoid use in patients with active peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in severe hepatic failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: When using high dosages (eg, analgesic or anti-inflammatory uses), use with caution and monitor renal function or consider the use of an alternative analgesic/anti-inflammatory agent (NKF [Henrich 1996]; Whelton 2000). Low-dose aspirin (eg, 75 to 162 mg daily) may be safely used in patients with any degree of renal impairment (KDOQI 2005; KDOQI 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alteplase: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of alteplase; administration within 24 hours increases the risk of hemorrhagic transformation (Jauch 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; COX-2 inhibitors/NSAIDs: When used concomitantly with &le;325 mg of aspirin, NSAIDs (including selective COX-2 inhibitors) substantially increase the risk of gastrointestinal complications (eg, ulcer); concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower GI bleed patients: An individualized and multidisciplinary approach should be used to manage patients with an acute lower GI bleed (LGIB) who are on antiplatelet medications. Aspirin for primary prevention of cardiovascular events should be avoided in most patients with LGIB who do not have established cardiovascular disease and do not have high risk factors for cardiovascular events. However, aspirin for secondary cardiovascular prevention should generally <i>not </i>be discontinued in patients with established cardiovascular disease and a history of lower GI bleeding (Strate 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: When used for self-medication (OTC labeling): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients should be instructed to contact their healthcare provider if these occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Aspirin should be avoided (if possible) in surgical patients for 1 to 2 weeks prior to elective surgery, to reduce the risk of excessive bleeding. In patients with cardiac stents or who have recently (within the previous 14 days) undergone balloon angioplasty that have not completed their full course of antiplatelet therapy (eg, dual antiplatelet therapy), antiplatelet therapy should be continued and elective surgery should be delayed until course of antiplatelet therapy is complete; patient specific situations should be discussed with cardiologist (ACC/AHA [Fleisher 2014]; ACC/AHA [Levine 2016]; AHA/ACC/SCAI/ACS/ADA [Grines 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resistance: Aspirin resistance is defined as measurable, persistent platelet activation that occurs in patients prescribed a therapeutic dose of aspirin. Clinical aspirin resistance, the recurrence of some vascular event despite a regular therapeutic dose of aspirin, is considered aspirin treatment failure. Proposed mechanisms of aspirin resistance include poor adherence with therapy, poor absorption, inadequate dosage, drug interactions, increased isoprostane activity, platelet hypersensitivity to agonists, increased COX-2 activity, COX-1 polymorphism, and platelet alloantigen 2 polymorphism of platelet glycoprotein IIIa. Estimates of biochemical aspirin resistance range from 5.5% to 60% depending on the population studied and the assays used (Gasparyan 2008). Patients with aspirin resistance may have a higher risk of cardiovascular events compared to those who are aspirin sensitive (Gum 2003). Aspirin resistance is likely dose-related but may be influenced by dynamic factors yet to be identified; further research is required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819770\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Do not use aspirin in pediatric patients &lt;18 years of age (APS 2016) who have or who are recovering from chickenpox or flu symptoms (due to the association with Reye syndrome); when using aspirin, changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; instruct patients and caregivers to contact their health care provider if these symptoms occur; patients should be kept current on their influenza and varicella immunizations. Although Reye syndrome has been observed in patients receiving prolonged, high-dose aspirin therapy after Kawasaki disease presentation; it has not been observed in pediatric patients receiving low (antiplatelet) dosing regimens. Patients with Kawasaki disease and presenting with influenza or viral illness should not receive aspirin; acetaminophen is suggested as an antipyretic in these patients, and an alternate antiplatelet agent is suggested for a minimum of 2 weeks (AHA [McCrindle 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137138\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137059\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12829&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Aspirin. Specifically, alcohol may increase the bleeding risk of aspirin. Alcohol (Ethyl) may diminish the therapeutic effect of Aspirin. Specifically, alcohol may interfere with the controlled release mechanism of extended release aspirin. Management: Monitor patients who drink 3 or more alcoholic drinks a day for increased bleeding while taking aspirin. Counsel patients about the risk of bleeding and discourage such consumption. Give extended release aspirin 2 hours before, or 1 hour after, alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Aspirin may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: Salicylates may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.  Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carisoprodol: Aspirin may increase serum concentrations of the active metabolite(s) of Carisoprodol. Specifically, Meprobamate concentrations may be increased. Aspirin may decrease the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Aspirin may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling states that low dose aspirin could be considered, but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Aspirin may enhance the adverse/toxic effect of Dexibuprofen. Dexibuprofen may diminish the cardioprotective effect of Aspirin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen.  Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Aspirin may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Aspirin may increase the serum concentration of Edoxaban.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Aspirin may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: Aspirin may diminish the therapeutic effect of Lesinurad. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Aspirin may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, aspirin may decrease the absorption of ascorbic acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, aspirin may decrease the absorption of ascorbic acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Aspirin may enhance the adverse/toxic effect of Nicorandil. Specifically, the risk of gastrointestinal ulceration and hemorrhage may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Aspirin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: Salicylates may diminish the therapeutic effect of Probenecid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Aspirin may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of other Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: Salicylates may decrease the serum concentration of Sulfinpyrazone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: Aspirin may enhance the adverse/toxic effect of Talniflumate.  Management: When possible, consider alternatives to this combination.  Concurrent use is generally not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Aspirin may decrease the protein binding of Thiopental. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in adult patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in adults receiving ticagrelor.  Canadian recommendations are to avoid adult daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiludronate: Aspirin may decrease the serum concentration of Tiludronate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Aspirin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Salicylates may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137088\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food may decrease the rate but not the extent of oral absorption. Benedictine liqueur, prunes, raisins, tea, and gherkins have a potential to cause salicylate accumulation. Fresh fruits containing vitamin C may displace drug from binding sites, resulting in increased urinary excretion of aspirin. Curry powder, paprika, licorice; may cause salicylate accumulation. These foods contain 6 mg salicylate/100 g. An ordinary American diet contains 10-200 mg/day of salicylate. Management: Administer with food or large volume of water or milk to minimize GI upset. Limit curry powder, paprika, licorice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137075\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Salicylates have been noted to cross the placenta and enter fetal circulation. Adverse effects reported in the fetus include mortality, intrauterine growth retardation, salicylate intoxication, bleeding abnormalities, and neonatal acidosis. Use of aspirin close to delivery may cause premature closure of the ductus arteriosus. Adverse effects reported in the mother include anemia, hemorrhage, prolonged gestation, and prolonged labor (&Oslash;stensen 1998).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Low-dose aspirin may be used to prevent preeclampsia in women with a history of early-onset preeclampsia and preterm delivery (&lt;34 0/7 weeks), or preeclampsia in &ge;1 prior to pregnancy (ACOG 2013). Treatment is started after 12 weeks' gestation in women at risk for preeclampsia (ACCP [Bates 2012]; LeFevre 2014). Low-dose aspirin is used to treat complications resulting from antiphospholipid syndrome in pregnancy (either primary or secondary to SLE) (ACCP [Bates 2012]; Carp 2004; Tincani 2003). Low-dose aspirin to prevent thrombosis may also be used during the second and third trimesters in women with prosthetic valves (mechanical or bioprosthetic). The use of warfarin is recommended, along with low-dose aspirin, in those with mechanical prosthetic valves (AHA/ACC [Nishimura 2014]). Low-dose aspirin may also be used after the first trimester in women with low-risk conditions requiring antiplatelet therapy (AHA/ASA [Kernan 2014]). When needed in doses required for the management of pain, agents other than aspirin are preferred in pregnant women and use in the third trimester is not recommended (K&auml;ll&eacute;n 2016; Shah 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051173\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, iron studies, ferritin, stools for occult blood, and renal function tests with prolonged therapy. Serum salicylate concentration with chronic use; may not be necessary in Kawasaki disease; <b>Note:</b> Decreased aspirin absorption and increased salicylate clearance has been observed in children with acute Kawasaki disease; these patients rarely achieve therapeutic serum salicylate concentrations; thus, monitoring of serum salicylate concentrations is not necessary in most of these children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051177\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Peak concentrations usually occur 2 hours after normal doses but may occur 6 to 24 hours after acute toxic ingestion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salicylate serum concentrations correlate with the pharmacological actions and adverse effects observed. See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Serum Salicylate: Clinical Correlations</caption>\n      <col align=\"center\"></col>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Serum Salicylate Concentration</p>\n            <p style=\"text-indent:0em;\">(mcg/mL)</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Desired Effects</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Adverse Effects / Intoxication</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&sim;100</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Antiplatelet</p>\n            <p style=\"text-indent:0em;\">Antipyresis</p>\n            <p style=\"text-indent:0em;\">Analgesia</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">GI intolerance and bleeding, hypersensitivity, hemostatic defects</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">150 to 300</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">Anti-inflammatory</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">Mild salicylism</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">250 to 400</p></td>\n          <td valign=\"middle\">\n            <p style=\"text-indent:0em;\">Treatment of rheumatic fever</p></td>\n          <td>\n            <p style=\"text-indent:0em;\">Nausea/vomiting, hyperventilation, salicylism, flushing, sweating, thirst, headache, diarrhea, and tachycardia</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;400 to 500</p></td>\n          <td></td>\n          <td>\n            <p style=\"text-indent:0em;\">Respiratory alkalosis, hemorrhage, excitement, confusion, asterixis, pulmonary edema, convulsions, tetany, metabolic acidosis, fever, coma, cardiovascular collapse, renal and respiratory failure</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137053\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Irreversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, via acetylation, which results in decreased formation of prostaglandin precursors; irreversibly inhibits formation of prostaglandin derivative, thromboxane A<sub>2</sub>, via acetylation of platelet cyclooxygenase, thus inhibiting platelet aggregation; has antipyretic, analgesic, and anti-inflammatory properties </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137071\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Immediate release: Platelet inhibition: Within 1 hour (nonenteric-coated). Onset of enteric-coated aspirin expected to be delayed (Eikelboom 2012). <b>Note:</b> Chewing nonenteric-coated or enteric-coated tablets results in inhibition of platelet aggregation within 20 minutes; therefore, nonenteric-coated tablets should be chewed in settings where a more rapid onset is required (eg, acute MI) and enteric-coated tablets may be chewed when a rapid effect is required and immediate release nonenteric-coated tablets are not available (Eikelboom 2012; Feldman 1999; Sai 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate release: 4 to 6 hours; however, platelet inhibitory effects last the lifetime of the platelet (~10 days) due to its irreversible inhibition of platelet COX-1 (Eikelboom 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Immediate release: Rapidly absorbed in stomach and upper intestine (Eikelboom 2012); Extended-release capsule: Rate of absorption is dependent upon food, alcohol, and gastric pH.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 10 L; readily into most body fluids and tissues; hydrolyzed to salicylate (active) by esterases in the GI mucosa, red blood cells, synovial fluid and blood</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Concentration dependent; as salicylate concentration increases, protein binding decreases: ~90% to 94% (to albumin) at concentrations &le;80 mcg/mL (Rosenberg 1981; Juurlink 2015); ~30% with concentrations seen in overdose (Juurlink 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hydrolyzed to salicylate (active) by esterases in GI mucosa, red blood cells, synovial fluid, and blood; metabolism of salicylate occurs primarily by hepatic conjugation; metabolic pathways are saturable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release: 50% to 75% reaches systemic circulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Parent drug: Plasma concentration: 15 to 20 minutes; Salicylates (dose dependent): 3 hours at lower doses (300 to 600 mg), 5 to 6 hours (after 1 g), 10 hours with higher doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Immediate release: ~1 to 2 hours (nonenteric-coated), 3 to 4 hours (enteric-coated) (Eikelboom 2012); Extended-release capsule: ~2 hours. <b>Note:</b> Chewing nonenteric-coated tablets results in a time to peak concentration of 20 minutes (Feldman 1999). Chewing enteric-coated tablets results in a time to peak concentration of 2 hours (Sai 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (75% as salicyluric acid, 10% as salicylic acid)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137074\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Durlaza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">162.5 mg (30): $216.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (36): $1.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (St Joseph Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (36): $1.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Stanback Headache Powders Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">650-200-32 mg (6): $1.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Aspirin Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (12): $17.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (12): $18.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Aspir-Low Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (250): $6.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (120): $2.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $1.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Bayer Aspirin EC Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (32): $2.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Ecotrin Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (75): $6.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (EcPirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $2.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Miniprin Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (120): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ascriptin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $7.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (100): $2.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bayer Aspirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (200): $10.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bufferin Extra Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (65): $6.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bufferin Low Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">81 mg (130): $5.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bufferin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 mg (65): $4.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137078\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AAS (AR, BR, ES);</li>\n      <li>Acard (PL);</li>\n      <li>Aceprin (HK, MY);</li>\n      <li>Acetard (FI);</li>\n      <li>Aceticil (BR);</li>\n      <li>Acetysal (BG);</li>\n      <li>Acitab (MX);</li>\n      <li>Adiprin (KW, QA);</li>\n      <li>Adiprin EC (JO);</li>\n      <li>Adiro (ES, MX, VE);</li>\n      <li>Albyl-E (NO);</li>\n      <li>Algina (PY);</li>\n      <li>Andol (HR);</li>\n      <li>Ansin (TW);</li>\n      <li>Antacsal-E (MX);</li>\n      <li>Anthrom (PH);</li>\n      <li>Aptor (ID);</li>\n      <li>Artebin (KR);</li>\n      <li>Asactal (HU);</li>\n      <li>Asam (LK);</li>\n      <li>Asapor (FI);</li>\n      <li>Asawin (CO);</li>\n      <li>Ascardia (ID);</li>\n      <li>ASP (HK);</li>\n      <li>Aspa (TW);</li>\n      <li>Aspec (LK, NZ);</li>\n      <li>Aspen (PH);</li>\n      <li>Aspenorm (UA);</li>\n      <li>Aspent (TH);</li>\n      <li>Aspex (IL);</li>\n      <li>Aspicard (ET, KW, SA);</li>\n      <li>Aspicot (KW, LB);</li>\n      <li>Aspilets (ID, PH, VN);</li>\n      <li>Aspilets EC (PH);</li>\n      <li>Aspimed (AE);</li>\n      <li>Aspin (BD, LK);</li>\n      <li>Aspinal (EG, QA);</li>\n      <li>Aspirax (RO);</li>\n      <li>Aspire (TW);</li>\n      <li>Aspirem (BB, BM, BS, BZ, CY, GY, JM, PR, SR, TT);</li>\n      <li>Aspirin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Aspirin Bayer (HK);</li>\n      <li>Aspirin Cardio (IL, SG);</li>\n      <li>Aspirina (CL, CO, CU, EC);</li>\n      <li>Aspirina efervescente (MX);</li>\n      <li>Aspirina Junior (MX);</li>\n      <li>Aspitor (PH);</li>\n      <li>Aspro (AT, CH, CZ, FR, GB, IT, KW, NL, NZ, SA);</li>\n      <li>Aspro Junior (QA);</li>\n      <li>Asprovit (EE);</li>\n      <li>Asrina (TH);</li>\n      <li>ASS (DE);</li>\n      <li>Asthromed (PH);</li>\n      <li>Astrix (HU, KR, LK, PH);</li>\n      <li>B-Aspirin (TH);</li>\n      <li>Bamyl (SE);</li>\n      <li>Bayaspirin Protect 100 (CN);</li>\n      <li>Bayaspirina (AR);</li>\n      <li>Bayer Aspirin Cardio (ZA);</li>\n      <li>Bayprin EC (PH);</li>\n      <li>Besprin (PH);</li>\n      <li>Bokey (SG, TW);</li>\n      <li>Bufferin (JO, UY);</li>\n      <li>Cafemol Childrens Size (ZW);</li>\n      <li>Caprin (GB, IE);</li>\n      <li>Cardioaspirina (CO, PE);</li>\n      <li>Cardiomagnyl (UA);</li>\n      <li>Cardioprin (HR, TW);</li>\n      <li>Cardioprin 100 (IL);</li>\n      <li>Cardioton (PE);</li>\n      <li>Cardiprin (HK, LK);</li>\n      <li>Cartia (PT);</li>\n      <li>Caspirin (MY);</li>\n      <li>Circlevein (KR);</li>\n      <li>Colfarit (CZ, HN);</li>\n      <li>Comoprin (TH);</li>\n      <li>Cortal (PH);</li>\n      <li>Dispril (AE, BE, BH, CY, EG, IQ, IR, JO, LB, LY, OM, QA, SA, SY, TR, YE);</li>\n      <li>Disprin (BB, BF, BJ, BM, BS, BZ, CI, ET, GB, GH, GM, GN, GY, HK, IE, IN, JM, KE, KW, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PK, PR, SC, SD, SG, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Ecasil (BR);</li>\n      <li>Ecorin (LK);</li>\n      <li>Ecosprin (BD);</li>\n      <li>Ecotrin (AR, CL, MX, NZ, TW);</li>\n      <li>Encine EM (TW);</li>\n      <li>Eskotrin (VE);</li>\n      <li>Frosit (ID);</li>\n      <li>Globentyl (DK);</li>\n      <li>Glocar (ID);</li>\n      <li>Godamed (IL);</li>\n      <li>Kardegic (HU);</li>\n      <li>Kidiprin (JO);</li>\n      <li>Lodosprin (BD);</li>\n      <li>Lopirin (TW);</li>\n      <li>Magnecyl (SE);</li>\n      <li>Melabon (DE);</li>\n      <li>Micropirin (MT);</li>\n      <li>Miniaspi 80 (ID);</li>\n      <li>Naspro (ID);</li>\n      <li>Neospin (BD);</li>\n      <li>Norspirinal (ID);</li>\n      <li>Novasen (KW);</li>\n      <li>Nu-Seals (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZM, ZW);</li>\n      <li>Nuasa (IE);</li>\n      <li>Nuprin (IE);</li>\n      <li>Plaquetasa (CR, GT, SV);</li>\n      <li>Proprin (GB);</li>\n      <li>Remin (AE);</li>\n      <li>Rhonal (KR, QA, VE);</li>\n      <li>Rodin (UA);</li>\n      <li>Salisalido (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Salospir (GR);</li>\n      <li>Sedergine (BE);</li>\n      <li>Tevapirin (IL);</li>\n      <li>Thomapyrin (AT);</li>\n      <li>Thrombo-Aspilets (ID);</li>\n      <li>Thrombo-ASS (EE);</li>\n      <li>Tromcor (PH);</li>\n      <li>V-AS (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy.<i> Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society (APS). <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 7th ed. Glenview, IL: 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-828.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aspirin [prescribing information]. Morristown, NJ: Bayer Corporation.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey DN, Weibert RT, Naylor AJ, Shaw RF. A study of salicylate and caffeine excretion in the breast milk of two nursing mothers. <i>J Anal Toxicol</i>. 1982;6(2):64-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7098450/pubmed\" target=\"_blank\" id=\"7098450\">7098450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Bulkowstein M, Benyamini L, et al, &ldquo;Use of Antibiotic and Analgesic Drugs During Lactation,&rdquo; <i>Drug Saf</i>, 2003, 26(13):925-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/14583068/pubmed\" target=\"_blank\" id=\"14583068\">14583068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates ER, Babb JD, Casey DE Jr, et al, &ldquo;ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting),&rdquo; <i>J Am Coll Cardiol</i>, 2007, 49(1):126-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17207736/pubmed\" target=\"_blank\" id=\"17207736\">17207736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &quot;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&quot; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley LM, Midgley FM, Watson DC, et al, &quot;Anticoagulation Therapy in Children With Mechanical Prosthetic Cardiac Valves,&quot; <i>Am J Cardiol</i>, 1985, 56(8):533-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo; <i>J Am Coll Cardiol</i>, 2005, 45(8):1295-1301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15837265/pubmed\" target=\"_blank\" id=\"15837265\">15837265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carp HJ, &ldquo;Antiphospholipid Syndrome in Pregnancy,&rdquo; <i>Curr Opin Obstet Gynecol</i>, 2004, 16(2):129-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15017341/pubmed\" target=\"_blank\" id=\"15017341\">15017341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo; <i>N Engl J Med</i>, 2001, 345(25):1809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11752357/pubmed\" target=\"_blank\" id=\"11752357\">11752357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. <i>Clin Pediatr (Phila)</i>. 1981;20(1):53-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7449246/pubmed\" target=\"_blank\" id=\"7449246\">7449246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. <i>N Engl J Med</i>. 2009;360:2066-2078.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study Of Ibuprofen Effects On Thromboxane B2 Concentrations In Aspirin-Treated Healthy Adult Volunteers,&rdquo; <i>Clin Ther</i>, 2005, 27 (2):185-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15811481/pubmed\" target=\"_blank\" id=\"15811481\">15811481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durlaza (aspirin) [prescribing information]. North Haven, CT: New Haven Pharmaceuticals, Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012:141(2)(supp):e89S-e119S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315278/pubmed\" target=\"_blank\" id=\"22315278\">22315278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    el Makhlouf A, Friedli B, Oberh&auml;nsli I, et al, &quot;Prosthetic Heart Valve Replacement in Children. Results and Follow-Up of 273 Patients,&quot; <i>J Thorac Cardiovasc Surg</i>, 1987, 93(1):80-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3796033/pubmed\" target=\"_blank\" id=\"3796033\">3796033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. <i>Am J Cardiol</i>. 1999;84(4):404-409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10468077/pubmed\" target=\"_blank\" id=\"10468077\">10468077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez JS, Sadaniantz A. Medical and revascularization management in acute coronary syndrome in renal patients. <i>Semin Nephrol</i>. 2001;21(1):25-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11172556/pubmed\" target=\"_blank\" id=\"11172556\">11172556</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM. Analgesic drugs in breast milk and plasma. <i>Clin Pharmacol Ther</i>. 1981;29(5):625-633.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7214793/pubmed\" target=\"_blank\" id=\"7214793\">7214793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furie KL, Kasner SE, Adams RJ, et al, &quot;Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&quot; <i>Stroke</i>, 2011, 42(1):227-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/20966421/pubmed\" target=\"_blank\" id=\"20966421\">20966421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. <i>J Am Coll Cardiol</i>. 2008;51(19):1829-1843.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/18466797 /pubmed\" target=\"_blank\" id=\"18466797 \">18466797 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24226806 /pubmed\" target=\"_blank\" id=\"24226806 \">24226806 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. <i>J Am Coll Cardiol</i>. 2003;41(6):961-965.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12651041 /pubmed\" target=\"_blank\" id=\"12651041 \">12651041 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. <i>New Eng J Med</i>. 1979;301(11):577-579.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/112475/pubmed\" target=\"_blank\" id=\"112475\">112475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. <i>Am J Kidney Dis</i>. 1996;27(1):162-165.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/8546133/pubmed\" target=\"_blank\" id=\"8546133\">8546133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jamali F, Keshavarz E. Salicylate excretion in breast milk. <i>Int J Pharm</i>. 1981;8:285-290.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juurlink DN, Gosselin S, Kielstein JT, et al; EXTRIP Workgroup. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP Workgroup. <i>Ann Emerg Med</i>. 2015;66(2):165-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25986310/pubmed\" target=\"_blank\" id=\"25986310\">25986310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Reis M. Ongoing pharmacological management of chronic pain in pregnancy. <i>Drugs</i>. 2016;76(9):915-924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/27154242/pubmed\" target=\"_blank\" id=\"27154242\">27154242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. <i>Am J Kidney Dis</i>. 2005;45(4 suppl 3):S1-S153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/15806502/pubmed\" target=\"_blank\" id=\"15806502\">15806502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. <i>Am J Kidney Dis</i>. 2007;49(2 suppl 2):S12-S154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/17276798/pubmed\" target=\"_blank\" id=\"17276798\">17276798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25679302 /pubmed\" target=\"_blank\" id=\"25679302 \">25679302 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeBlanc JG, Sett SS, and Vince DJ, &quot;Antiplatelet Therapy in Children With Left-Sided Mechanical Prostheses,&quot; <i>Eur J Cardiothorac Surg</i>, 1993, 7(4):211-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/8481259/pubmed\" target=\"_blank\" id=\"8481259\">8481259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeFevre ML; US Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: US Preventive Services Task Force recommendation statement. <i>Ann Intern Med</i>. 2014;161(11):819-826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25200125/pubmed\" target=\"_blank\" id=\"25200125\">25200125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &quot;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&quot; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy G, &quot;Clinical Pharmacokinetics of Aspirin,&quot; <i>Pediatrics</i>, 1978, 62(5 Pt 2 Suppl):867-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/724339/pubmed\" target=\"_blank\" id=\"724339\">724339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li L, Li W, Chen CZ, Yi ZH, Zhou YY. Is aspirin use associated with age-related macular degeneration? A meta-analysis. <i>J Clin Pharm Ther</i>. 2015;40(2):144-154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25475899 /pubmed\" target=\"_blank\" id=\"25475899 \">25475899 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maalouf R, Mosley M, James Kallail K, et al, &quot;A Comparison of Salicylic Acid Levels in Normal Subjects After Rectal Versus Oral Dosing,&quot; <i>Acad Emerg Med</i>, 2009, 16(2):157-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/19076101/pubmed\" target=\"_blank\" id=\"19076101\">19076101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(12):3754-3832.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/25355838 /pubmed\" target=\"_blank\" id=\"25355838 \">25355838 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg NA, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),&quot; <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/24589852 /pubmed\" target=\"_blank\" id=\"24589852 \">24589852 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al, &quot;2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2013, 127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3247304/pubmed\" target=\"_blank\" id=\"3247304\">3247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, Khamashta M, Lockshin M, &quot;Anti-inflammatory and Immunosuppressive Drugs and Reproduction,&quot; <i>Arthritis Res Ther</i>, 2006, 8(3):209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/16712713/pubmed\" target=\"_blank\" id=\"16712713\">16712713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, &ldquo;Nonsteroidal Anti-inflammatory Drugs During Pregnancy,&rdquo; <i>Scand J Rheumatol Suppl</i>, 1998, 107:128-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/9759151/pubmed\" target=\"_blank\" id=\"9759151\">9759151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&quot; 6th ed. Glenview, IL: American Pain Society; 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg J, Benowitz NL, Pond S. Pharmacokinetics of drug overdose. <i>Clin Pharmacokinet</i>. 1981;6(3):161-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/7016383/pubmed\" target=\"_blank\" id=\"7016383\">7016383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sai Y, Kusaka A, Imanishi K, et al. A randomized, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets in healthy volunteers. <i>J Pharm Sci</i>. 2011;100(9):3884-3891.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/21544823/pubmed\" target=\"_blank\" id=\"21544823\">21544823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serra AJ, McNicholas KW, Olivier HF Jr, et al, &quot;The Choice of Anticoagulation in Pediatric Patients With the St. Jude Medical Valve Prostheses,&quot; <i>J Cardiovasc Surg (Torino)</i>, 1987, 28(5):588-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3654744/pubmed\" target=\"_blank\" id=\"3654744\">3654744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah S, Banh ET, Koury K, Bhatia G, Nandi R, Gulur P. Pain management in pregnancy: multimodal approaches. <i>Pain Res Treat</i>. 2015;2015:987483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26448875/pubmed\" target=\"_blank\" id=\"26448875\">26448875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &quot;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&quot; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solymar L, Rao PS, Mardini MK, et al, &quot;Prosthetic Valves in Children and Adolescents,&quot; <i>Am Heart J</i>, 1991, 121(2 Pt 1):557-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/1990763/pubmed\" target=\"_blank\" id=\"1990763\">1990763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O and Hagg S, &ldquo;Analgesics and Breast-Feeding: Safety Considerations,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(3):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/10937472/pubmed\" target=\"_blank\" id=\"10937472\">10937472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. <i>Nephrourol Mon</i>. 2015;7(4):e28099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/26528445/pubmed\" target=\"_blank\" id=\"26528445\">26528445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tincani A, Branch W, Levy RA, et al, &ldquo;Treatment of Pregnant Patients With Antiphospholipid Syndrome,&rdquo; <i>Lupus</i>, 2003, 12(7):524-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/12892392/pubmed\" target=\"_blank\" id=\"12892392\">12892392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR. Serum salicylate levels in a breast fed infant. <i>Ann Rheum Dis</i>. 1987;46(8):638-639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/3662653/pubmed\" target=\"_blank\" id=\"3662653\">3662653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):637S-668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/22315274 /pubmed\" target=\"_blank\" id=\"22315274 \">22315274 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. <i>Am J Ther</i>. 2000;7(2):63-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aspirin-pediatric-drug-information/abstract-text/11319575/pubmed\" target=\"_blank\" id=\"11319575\">11319575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs,&quot; 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/index.html </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Rheumatic Fever and Rheumatic Heart Disease,&quot; 2004. Available at http://www.who.int/cardiovascular_diseases/resources/trs923/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12829 Version 166.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137093\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F137094\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051174\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12669217\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051166\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137065\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F137050\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051179\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F137087\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051178\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F137154\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137152\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137072\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137054\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819770\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F137138\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137059\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137088\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F137075\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051173\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1051177\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137053\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F137071\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137074\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F137078\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12829|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin: Drug information</a></li><li><a href=\"topic.htm?path=aspirin-patient-drug-information\" class=\"drug drug_patient\">Aspirin: Patient drug information</a></li></ul></div></div>","javascript":null}